BROSSARD, Quebec — August 15, 2025 — Leads & Copy — Diagnos Inc. intends to extend the exercise period of 650,000 stock warrants, initially part of a non-brokered private placement announced on March 22, 2024. Subject to TSX Venture Exchange consent, the expiry date will be extended to August 5, 2026. All other warrant provisions remain unchanged.
DIAGNOS also corrected its August 13th press release, stating the expiry date for 1,414,286 warrants issued from a February 27, 2024, private placement is August 5, 2026, not February 27, 2029. The company apologized for any confusion.
A follow-up release will be issued only if the Exchange rejects the amendment application.
DIAGNOS is a Canadian corporation focused on early detection of critical eye-related health problems using AI.
Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224
Source: DIAGNOS Inc.
